|
Kollaboration mit Pharming Group N.V.
ir.orchard-tx.com/news-releases/...oup-announce-collaboration
Eine mögliche Erklärung wären Mittelabflüße aus Biotech ETF´s. Wer gut durch solche Zeiten kommen will machts am besten wie "die Großen" und parkt sein Geld in Aktien wie Novo Nordisk (profitabel, zahlt Dividende, 52 Wochen-Hoch, wenig volatil).
zurück zu Orchard - die Zahlen für Q1/21
Cash and Investments of Approximately $300M Provide Runway into First Half 2023
ir.orchard-tx.com/news-releases/...rst-quarter-2021-financial
www.pharmatimes.com/news/...tics_gene_therapy_libmeldy_1373028
Q3/22 Zahlen
- runway now into the second quarter of 2024
ir.orchard-tx.com/news-releases/...ird-quarter-2022-financial
1/10 RS
ir.orchard-tx.com/news-releases/...completes-ads-ratio-change
Zahlen für FY22
- OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA)
- Strategic financing from leading healthcare investors provides up to $188 million of additional capital upon achievement of key milestones
ir.orchard-tx.com/news-releases/...ss-update-and-reports-2022
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
54 | Reboundkanditat Orchard Therapeutics | moneywork4me | Vassago | 30.11.23 13:26 |